Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04786340 · ClinicalTrials.gov registry record · Phase 2
A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy
A Phase 2 study, sponsored by WinSanTor.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT04786340: Completed Phase 2 study, sponsored by WinSanTor.
NCT04786340 is a Phase 2 study that has completed, run by WinSanTor. The registered enrollment target is 58 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04786340, a Phase 2 study, has completed, sponsored by WinSanTor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects with Type II Diabetes and painful peripheral neuropathy.
Primary Outcome
Safety will be assessed by observing changes in patients' blood tests when compared to normal lab values/ranges after once daily dosing of 1 dose level of WST-057 solution or placebo. The number of participants with treatment-related adverse events as assessed by CTCAEv4.0 will be reported.
Interventions
- DRUG Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution
- DRUG Placebo: WST-057 4mL topical solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2022-12-08 |
| Phase | Phase 2 |
What the finished NCT04786340 record still lists
NCT04786340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution is the first listed.
NCT04786340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04786340 about?
NCT04786340 is a clinical study titled "A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy". This is a 12 week, 2-arm, blinded, single-site, placebo-controlled Phase II study in subjects with Type II Diabetes and painful peripheral neuropathy.
What is the current status of trial NCT04786340?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2020-11-20. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT04786340?
The interventions under investigation include: Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution (DRUG), Placebo: WST-057 4mL topical solution (DRUG).
Who is sponsoring clinical trial NCT04786340?
This trial is sponsored by WinSanTor, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04786340's enrollment target sits among peer trials
58 1135th of 2000 higher than 860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI